Jpmorgan Chase & Co »

Oncternal Therapeutics shares owned by Jpmorgan Chase & Co

Quarter-by-quarter ownership of Oncternal Therapeutics (ONCT) shares owned by Jpmorgan Chase & Co from 13F filings

Historical chart of Jpmorgan Chase & Co investment in Oncternal Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Oncternal Therapeutics held by Jpmorgan Chase & Co consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Oncternal Therapeutics by Jpmorgan Chase & Co

Quarter filed Position value Share count Share price at filing
2024-06-30 $7.6k 1.0k 7.60
2024-03-31 $9.0k 1.0k 9.00

More positions owned by Jpmorgan Chase & Co

Microsoft Corp Common (MSFT)
Nvidia Corporation Common (NVDA)
Apple Common (AAPL)
Amazon Common (AMZN)
Spdr S&p 500 Etf (SPY)
Meta Platforms Common (META)
Alphabet Common (GOOG)
Eli Lilly & Co Common (LLY)
Unitedhealth Group Common (UNH)
Mastercard Incorporated Common (MA)
Broadcom Common (AVGO)
Alphabet Common (GOOGL)
Vanguard Total Intl Bond Etf Fund (BNDX)
Vanguard S&p 500 Etf idx (VOO)
Ishares Core S&p 500 Etf Fund (IVV)

View all positions for Jpmorgan Chase & Co

Top funds holding Oncternal Therapeutics

Vanguard Group
Millennium Management
BlackRock
Dimensional Fund Advisors
Geode Capital Management
Pasadena Private Wealth
Richmond Brothers
Renaissance Technologies
Susquehanna International
Morgan Stanley
Quantum Private Wealth
Acadian Asset Management
Jpmorgan Chase & Co
Tower Research Capital
Wells Fargo & Company

View all funds holding Oncternal Therapeutics